Your browser is no longer supported. Please, upgrade your browser.
Intec Pharma Ltd
Index- P/E- EPS (ttm)-14.62 Insider Own2.72% Shs Outstand4.82M Perf Week6.41%
Market Cap21.28M Forward P/E- EPS next Y-9.80 Insider Trans0.00% Shs Float4.69M Perf Month-31.02%
Income-14.50M PEG- EPS next Q-2.56 Inst Own14.70% Short Float2.82% Perf Quarter-36.81%
Sales- P/S- EPS this Y85.50% Inst Trans- Short Ratio0.13 Perf Half Y-48.99%
Book/sh10.27 P/B0.94 EPS next Y-181.90% ROA-68.90% Target Price13.00 Perf Year-70.91%
Cash/sh- P/C- EPS next 5Y- ROE-96.40% 52W Range8.80 - 36.88 Perf YTD-30.22%
Dividend- P/FCF- EPS past 5Y26.00% ROI- 52W High-73.89% Beta1.11
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low9.43% ATR1.92
Employees70 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)39.14 Volatility25.72% 14.28%
OptionableNo Debt/Eq0.00 EPS Q/Q42.00% Profit Margin- Rel Volume1.01 Prev Close9.63
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume990.54K Price9.63
Recom2.30 SMA20-22.17% SMA50-31.65% SMA200-39.66% Volume0 Change0.00%
Dec-09-20Upgrade Ladenburg Thalmann Neutral → Buy $13
Oct-11-19Downgrade ROTH Capital Buy → Neutral $10 → $1
Mar-26-18Reiterated Maxim Group Buy $8 → $12
Feb-28-18Initiated Ladenburg Thalmann Buy
Feb-26-18Initiated H.C. Wainwright Buy
Sep-21-17Reiterated Oppenheimer Outperform $10 → $15
Sep-16-15Initiated Maxim Group Buy $9
Sep-11-15Initiated ROTH Capital Buy $9.50
Aug-03-21 07:46PM  
Jul-29-21 07:01PM  
Jul-26-21 08:00AM  
May-13-21 07:15PM  
May-11-21 01:49PM  
May-06-21 02:45PM  
May-04-21 05:12PM  
Apr-28-21 12:40PM  
Apr-27-21 07:39PM  
Apr-20-21 03:48PM  
Apr-14-21 03:16PM  
Apr-13-21 07:00PM  
Apr-07-21 06:16PM  
Apr-06-21 02:45PM  
Mar-31-21 02:06PM  
Mar-30-21 06:56PM  
Mar-26-21 11:02PM  
Mar-23-21 02:26PM  
Mar-22-21 08:16PM  
Mar-21-21 03:22AM  
Mar-20-21 12:52PM  
Mar-17-21 01:47PM  
Mar-16-21 08:18PM  
Mar-15-21 08:00AM  
Feb-10-21 04:17AM  
Dec-09-20 07:00AM  
Nov-05-20 07:00AM  
Oct-29-20 08:00AM  
Oct-08-20 07:00AM  
Sep-14-20 04:30PM  
Sep-08-20 07:00AM  
Aug-07-20 04:28PM  
Aug-05-20 07:00AM  
Jun-13-20 09:04AM  
Jun-05-20 12:00PM  
Jun-02-20 10:03AM  
May-28-20 08:00AM  
May-11-20 04:15PM  
May-04-20 03:33PM  
Mar-26-20 01:05PM  
Mar-13-20 07:30AM  
Feb-25-20 07:30AM  
Jan-30-20 10:44PM  
Jan-09-20 07:00AM  
Dec-23-19 07:51PM  
Dec-11-19 07:30AM  
Dec-06-19 07:30AM  
Dec-03-19 07:30AM  
Nov-13-19 07:00AM  
Nov-12-19 07:00AM  
Sep-25-19 07:00AM  
Sep-16-19 07:00AM  
Sep-03-19 07:00AM  
Aug-30-19 11:28AM  
Aug-13-19 10:09AM  
Aug-09-19 07:00AM  
Aug-06-19 12:00PM  
Jul-22-19 10:15AM  
Jul-03-19 05:00PM  
Jul-01-19 09:00AM  
Jun-28-19 05:45PM  
Jun-25-19 07:00AM  
Jun-19-19 07:00AM  
May-28-19 07:00AM  
May-20-19 07:00AM  
May-16-19 06:00AM  
May-07-19 07:00AM  
May-02-19 07:00AM  
Apr-30-19 07:00AM  
Apr-24-19 11:30AM  
Apr-01-19 07:00AM  
Mar-27-19 06:00AM  
Mar-13-19 07:00AM  
Feb-28-19 09:42AM  
Feb-27-19 07:00AM  
Feb-20-19 10:03AM  
Feb-19-19 07:00AM  
Jan-04-19 07:00AM  
Jan-02-19 07:00AM  
Dec-23-18 02:39AM  
Dec-19-18 09:28AM  
Dec-13-18 09:15AM  
Dec-11-18 10:37AM  
Dec-06-18 07:00AM  
Dec-03-18 06:50AM  
Nov-21-18 08:55AM  
Nov-09-18 07:00AM  
Nov-07-18 09:43AM  
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was incorporated in 2000 and is based in Jerusalem, Israel.